Frequency and Effect of Adjuvant Radiation Therapy Among Women With Stage I Endometrial Adenocarcinoma

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Endometrial cancer remains the most common gynecological malignancy in the United States; however, the optimal adjuvant treatment for stage I endometrial adenocarcinoma remains elusive despite published results from randomized trials. Recent publications have revealed 5-year overall survival rates of 80% to 90% for women with stage I disease who have received total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) and adjuvant radiation therapy (RT) based on clinical and pathological characteristics.1-7 Despite these encouraging results, the specific subgroup of patients with American Joint Committee on Cancer stage IC (>50% myometrial invasion) and high-grade disease (grade 3 or 4) are known to have relatively poorer outcomes with higher rates of both local and distant relapses.8

This publication has 12 references indexed in Scilit: